Ophthotech will begin an open-label phase 2a clinical trial of Zimura, a complement factor C5 inhibitor for patients with wet age-related macular degeneration, according to a press release.
Zimura (avacincaptad pegol) will be administered in combination with Lucentis (ranibizumab, Genentech) in patients who have not previously been treated with anti-VEGF drugs. A range of dosing regimens will be assessed, the release said.
“We believe that supplementing anti-VEGF therapy with a complement inhibitor such as Zimura may have the potential to further the efficacy of anti-VEGF monotherapy in wet AMD,” Kourous A. Rezaei, MD, senior vice president of medical strategy at Ophthotech, said in the release.
Two additional trials of Zimura will also begin before the end of the year, the company announced. One will study the drug as monotherapy for Stargardt disease, while the second will be an open-label phase 2a study evaluating it in combination with anti-VEGF therapy for idiopathic polypoidal choroidal vasculopathy.
A phase 2a clinical trial of Zimura monotherapy for intermediate/posterior noninfectious uveitis will begin in 2018.